USE OF CARBETOCIN FOR PREVENTING POSTPARTUM HEMORRHAGE

  • Authors: BAYEV O.R1,2
  • Affiliations:
    1. Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
    2. I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
  • Issue: No 7 (2013)
  • Pages: 101-105
  • Section: Articles
  • URL: https://journals.eco-vector.com/0300-9092/article/view/247072
  • ID: 247072

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Carbetocin is a long-acting structural analogue of natural human oxytocin. As compared to oxytocin, the carbetocin molecule is better protected from the effects of aminopeptidases and disulfidases, prolonging the half-life and decreasing the likelihood of enzymatic degradation, which in turn potentiates the functional and pharmacological properties of the agent. Carbetocin is effective in preventing postpartum hemorrhage in both high- and low-risk groups, not being inferior or superior to oxytocin or syntometrine in its action. Compared to oxytocin that should be used as long-term dropwise infusions to ensure a prolonged effect, carbetocin is administered once. The safety profile of carbetocin is similar to that of oxytocin. As compared to ergometrine-containing drugs, carbetocin much less causes side effects and it may be used in a wider range of patients, including parturients with arterial hypertension and preeclampsia (gestosis).

Full Text

Restricted Access

About the authors

O. R BAYEV

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia

Email: metod_obsgyn@hotmail.com
Department of Obstetrics, Gynecology, Perinatology, and Reproductology, Faculty for Postgraduate Training of Physicians

References

  1. Khan K.S., Wojdyla D., Say L., Gülmezoglu A.M., Van Look P.F. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006; 367: 1066—74.
  2. Ronsmans C., Graham W. Maternal mortality. Mortality: who, when, where and why. Lancet. 2006; 368: 1189—2000.
  3. Айламазян Э.К., Репина М.А., Кузьминых Т.У. Акушерские кровотечения (профилактика и лечение). Акушерство и гинекология. 2009; 3: 15—9.
  4. Савельева Г.М., Курцер М.А., Шалина Р.И. Материнская смертность и пути ее снижения. Акушерство и гинекология. 2009; 3: 11—4.
  5. Серов В.Н. Профилактика материнской смертности. Русский медицинский журнал. 2008; 16(1): 3—5.
  6. Driessen M., Bouvier-Colle M.-H., Dupont C., Khoshnood B., Rudigoz R.C., Deneux-Tharaux C. Postpartum hemorrhage resulting from uterine atony after vaginal delivery factors associated with severity. Obstet. Gynecol. 2011; 117(1): 21—31.
  7. Oyelese Y., Scorza W.E., Mastrolia R., Smulian J. C. Postpartum hemorrhage. Obstet. Gynecol. Clin. North Am. 2007; 34(3): 421—41.
  8. Prendiville W.J., Elbourne D., McDonald S.J. WITHDRAWN: Active versus expectant management in the third stage of labour. Cochrane Database Syst. Rev. 2009; (3): CD000007.
  9. Баев О.Р. Профилактика кровотечений в послеродовом и раннем послеродовом периоде. Какие использовать препараты? Акушерство и гинекология. 2011; 7: 16—20.
  10. Chong Y.S., Su L.L., Arulkumaran S. Current strategies for the prevention of postpartum haemorrhage in the third stage of labour. Curr. Opin. Obstet. Gynecol. 2004; 16(2): 143—50.
  11. Manrique Munoz S., Munar Bauzà F., Francés González S., Suescun López M.C., Montferrer Estruch N., Fernández López de Hierro C. Update on the use of uterotonic agents. Rev. Esp. Anestesiol. Reanim. 2012; 59(2): 91—7.
  12. Peters N.C., Duvekot J.J. Carbetocin for the prevention of postpartum hemorrhage: a systematic review. Obstet. Gynecol. Surv. 2009; 64(2): 129—35.
  13. Callaghan W.M., Kuklina E.V., Berg C.J. Trends in postpartum hemorrhage: United States, 1994—2006. Am. J. Obstet. Gynecol. 2010; 202(4): 353.
  14. Cameron C.A., Roberts C.L., Olive E.C., Ford J.B., Fischer W.E. Trends in postpartum haemorrhage. Aust. N. Z. J. Publ. Health. 2006; 30(2): 151—6.
  15. Knight M., Callaghan W.M., Berg C., Alexander S. Trends in postpartum hemorrhage in high resource countries: a review and recommendations from the International Postpartum Hemorrhage Collaborative Group. BMC Pregnancy Childbirth. 2009; 9: 55.
  16. Lutomski J.E., Byrne B.M., Devane D., Greene R.A. Increasing trends in atonic postpartum haemorrhage in Ireland: an 11-year population-based cohort study. Br. J. Obstet. Gynaecol. 2012; 119(3): 306—14.
  17. Tita A.T., Szychowski J.M., Rouse D.J., Bean C.M., Chapman V., Nothern A. et al. Higher-dose oxytocin and hemorrhage after vaginal delivery: a randomized controlled trial. Obstet. Gynecol. 2012; 119(2,Pt1): 293—300.
  18. Dyer R.A., Butwick A.J., Carvalho B. Oxytocin for labour and caesarean delivery: implications for the anaesthesiologist. Curr. Opin. Anaesthesiol. 2011; 24(3): 255—61.
  19. Sartain J.B., Barry J.J., Howat P. W., McCormack D.I., Bryant M. Intravenous oxytocin bolus of 2 units is superior to 5 units during elective caesarean section. Br. J. Anaesth 2008; 101: 822—6.
  20. Butwick A.J., Coleman L., Cohen S.E., Riley E.T., Carvalho B. Minimum Effective bolus dose of oxytocin during elective cesarean delivery. Br. J. Anaesth. 2010; 104(3): 338—43.
  21. Leduc D., Senikas V., Lalonde A.B., Ballerman C., Biringer A., Delaney M. et al. Active management of the third stage of labour: prevention and treatment of postpartum hemorrhage. J. Obstet. Gynaecol. Can. 2009; 31(10): 980—93.
  22. Harriott J., Christie L., Wynter S., DaCosta V., Fletcher H., Reid M. A randomized comparison of rectal misoprostol with syntometrine on blood loss in the third stage of labour. West Indian Med. J. 2009; 58(3): 201—6.
  23. Singh G., Radhakrishnan G., Guleria K. Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. Int. J. Gynaecol. Obstet. 2009; 107(2):130—4.
  24. Vaid A., Dadhwal V., Mittal S., Deka D., Misra R., Sharma J.B., Vimla N. A randomized controlled trial of prophylactic sublingual misoprostol versus intramuscular methyl-ergometrine versus intramuscular 15-methyl PGF2alpha in active management of third stage of labor. Arch. Gynecol. Obstet. 2009; 280(6): 893—7.
  25. Gülmezoglu A.M., Villar J., Ngoc N.T., Piaggio G., Carroli G., Adetoro L. et al.; WHO Collaborative Group To Evaluate Misoprostol in the Management of the Third Stage of Labour. WHO multicentre randomised trial of misoprostol in the management of the third stage of labour. Lancet. 2001; 358(9283): 689—95.
  26. Gülmezoglu A.M., Forna F., Villar J., Hofmeyr G.J. Prostaglandins for preventing postpartum haemorrhage. Cochrane Database Syst. Rev. 2007; (3): CD000494.
  27. Lalonde A., Daviss B.A., Acosta A., Herschderfer K. Postpartum hemorrhage today: ICM/FIGO initiative 2004-2006. Int. J. Gynaecol. Obstet. 2006; 94(3): 243—53.
  28. Patted S.S., Goudar S.S., Naik V.A., Bellad M.B., Edlavitch S.A., Kodkany B.S. et al. Side effects of oral misoprostol for the prevention of postpartum hemorrhage: results of a community-based randomised controlled trial in rural India. J. Matern. Fetal Neonatal Med. 2009; 22(1): 24—8.
  29. Bajcsy A.C., Szenci O., van der Weijden G.C., Doornenbal A., Maassen F., Bartyik J., Taverne M.A. The effect of a single oxytocin or carbetocin treatment on uterine contractility in early postpartum dairy cows. Theriogenology. 2006; 65(2): 400—14.
  30. Steckler D., Naidoo V., Gerber D., Kähn W. Ex vivo influence of carbetocin on equine myometrial muscles and comparison with oxytocin. Theriogenology. 2012; 78(3): 502—9.
  31. Schramme A.R., Pinto C.R., Davis J., Whisnant C.S., Whitacre M.D. Pharmacokinetics of carbetocin, a long-acting oxytocin analogue, following intravenous administration in horses. Equine Vet. J. 2008; 40(7): 658—61.
  32. Hunter D.J., Schulz P., Wassenaar W. Effect of carbetocin, a long-acting oxytocin analog on the postpartum uterus. Clin. Pharmacol. Ther. 1992; 52(1): 60—7.
  33. Van Dongen P.W., Verbruggen M.M., de Groot A.N., van Roosmalen J., Sporken J.M., Schulz M. Ascending dose tolerance study of intramuscular carbetocin administered after normal vaginal birth. Eur. J. Obstet. Gynecol. Reprod. Biol. 1998; 77(2): 181—7.
  34. Boucher M., Nimrod C.A., Tawagi G.F. Comparison of carbetocin and oxytocin for the prevention of postpartum hemorrhage following vaginal delivery: a double-blind randomized trial. J. Obstet. Gynaecol. Can. 2004; 26(5): 481—8.
  35. Leung S., Ng P., Wong W., Cheung T. A randomised trial of carbetocin versus syntometrine in the management of the third stage of labour. Br. J. Obstet. Gynaecol. 2006; 113: 1459—64.
  36. Rashid M., Clark A., Rashid M.H. A randomised controlled trial comparing the efficacy of intramuscular syntometrine and intravenous syntocinon, in preventing postpartum haemorrhage. J. Obstet. Gynaecol. 2009; 29(5): 396—401.
  37. Choy C.M., Lau W.C., Tam W.H., Yuen P.M. A randomized controlled trial of intramuscular syntometrine and intravenous oxytocin in the management of the third stage of labour. Br. J. Obstet. Gynaecol. 2002; 109: 173—7.
  38. McDonald S., Abbott J.M., Higgins S.P. Prophylactic ergometrine-oxytocin versus oxytocin for the third stage of labour. Cochrane Database Syst. Rev. 2004; (1): CD00021.
  39. Dumoulin J.G. A reappraisal of the use of ergometrine. J. Obstet. Gynaecol. 1981; 1: 178—81.
  40. Carey M. Adverse cardiovascular sequelae of ergometrine. Br. J. Obstet. Gynaecol. 1993; 100(9): 865.
  41. Su L.L., Rauff M., Chan Y.H., Mohamad Suphan N., Lau T.P., Biswas A., Chong Y.S. Carbetocin versus syntometrine for the third stage of labour following vaginal delivery-- a doubleblind randomised controlled trial. Br. J. Obstet. Gynaecol. 2009; 116(11): 1461—6.
  42. Ngan L., Keong W., Martins R. Carbetocin versus a combination of oxytocin and ergometrine in control of postpartum blood loss. Int. J. Gynaecol. Obstet. 2007; 97(2): 152—3.
  43. Askar A.A., Ismail M.T., El-Ezz A.A., Rabie N.H. Carbetocin versus syntometrine in the management of third stage of labor following vaginal delivery. Arch. Gynecol. Obstet. 2011; 284(6): 1359—65.
  44. Nirmala K., Zainuddin A.A., Ghani N.A., Zulkifli S., Jamil M.A. Carbetocin versus syntometrine in prevention of post-partum hemorrhage following vaginal delivery. J. Obstet. Gynaecol. Res. 2009; 35(1): 48—54. Rath W. Prevention of postpartum haemorrhage with the oxytocin analogue carbetocin. Eur. J. Obstet. Gynecol. Reprod. Biol. 2009; 147(1): 15—20.
  45. Rath W. Prevention of postpartum haemorrhage with the oxytocin analogue carbetocin. Eur. J. Obstet. Gynecol. Reprod. Biol. 2009; 147(1): 15—20.
  46. Davies G., Tessier J., Woodman M. Maternal hemodynamics after oxytocin bolus compared with infusion in the third stage of labor: a randomized controlled trial. Obstet. Gynecol. 2005; 105: 294—9.
  47. Svanstrom M.C., Biber B., Hanes M., Johansson G., Naslund U., Balfors E.M. Signs of myocardial ischaemia after injection of oxytocin: a randomized double-blind comparison of oxytocin and methylergometrine during Caesarean section. Br. J. Anaesth. 2008; 100: 683—9.
  48. Thomas J.S., Koh S.H., Cooper G.M. Haemodynamic effects of oxytocin given as i.v. bolus or infusion on women undergoing Caesarean section. Br. J. Anaesth. 2007; 98(1): 116—9.
  49. Jago A.A., Ezechi O.C., Achinge G.I., Okunlola M.A. Effect of oxytocics on the blood pressure of normotensive Nigerian parturients. J. Matern. Fetal Neonatal Med. 2007; 20(9): 703—5.
  50. Su L.L., Chong Y.S., Samuel M. Carbetocin for preventing postpartum haemorrhage. Cochrane Database Syst. Rev. 2012; (4): CD005457.
  51. Grotegut C.A., Paglia M.J., Johnson L.N., Thames B., James A.H. Oxytocin exposure in women with postpartum hemorrhage secondary to uterine atony. Am. J. Obstet. Gynecol. 2011; 204(1): 56; e1—6.
  52. Reyes O.A., Gonzalez G.M. Carbetocin versus oxytocin for prevention of postpartum hemorrhage in patients with severe preeclampsia: a double-blind randomized controlled trial. J. Obstet. Gynaecol. Can. 2011; 33(11): 1099—104.
  53. Del Angel-Garcia G., Garcia-Contreras F., Constantino-Casas P., Nevarez-Sida A., Lopez-Gonzalez N., Garcia-Constantino M. et al. Economic evaluation of сarbetocin for the prevention of uterine atony in patients with risk factors in Mexico. Value in Health. 2006; 9(6): A254.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies